Evidence map›Paper›PMID 39872799›Full record

ArticleEuropean clinical respiratory journal2025

The complexities of elexacaftor/tezacaftor/ivacaftor therapeutic drug monitoring in a person with cystic fibrosis and

Claire Y Mou, Daniel J Henderson, Angela G Matson, Karen M Herd, David W Reid, Timothy Riddles, Ellie Johnson, Brett McWhinney, Rebecca Swenson, Andrew Burke and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI).Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2026
    Trial
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Claire Y MouAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Daniel J HendersonAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Angela G MatsonAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Karen M HerdAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
David W ReidAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Timothy RiddlesAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Ellie JohnsonAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Brett McWhinneyDepartment of Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia.
Rebecca SwensonDepartment of Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia.
Andrew BurkeAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Ieuan E S EvansAdult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.ORCID https://orcid.org/0000-0002-9669-0805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory

Indexed as

Cystic Fibrosiselexacaftor/tezacaftor/ivacaftorKaftrionon-tuberculous mycobacteriaTherapeutic drug monitoringTrikafta

Identifiers

PMID39872799
PMCPMC11770854

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.